Avandia, Actos To Accelerate Market Growth With Rezulin's Withdrawal

The removal of Warner-Lambert's Rezulin will boost sales of the two newer antidiabetic "glitazones," SmithKline Beecham/Bristol-Myers Squibb's Avandia and Lilly/Takeda's Actos.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet